Blair Clark-Schoeb, chief communications officer, joined Lykos Therapeutics as a member of the executive committee in September 2022. She is an experienced communications professional having worked in public relations (PR), investor relations (IR), government affairs (GA) and patient advocacy (PA) with biotechnology and life sciences companies for more than 20 years. Most recently, Blair ran communications and was a member of the leadership team at Aruvant, a subsidiary of a publicly traded company, Roivant. Prior to that, she headed up the communications effort at Zyla Life Sciences, a publicly traded company that was acquired by Assertio. At both of those companies she led the IR, PR, GA and PA work and managed all internal and external communications. Before working in-house, Blair led her own consulting business, BiotechComm, working with pharmaceutical and biotechnology companies such as Sanofi, Syndax and Horizon Therapeutics. Prior to running BiotechComm, she worked in IR and PR at two different agencies, Burns McClellan and Real Chemistry, and did investment banking at Donaldson, Lufkin and Jenrette. Blair received her undergraduate degree in Psychology from Harvard University and her master’s in healthcare innovation from the University of Pennsylvania. She was a founding member of the Society of Healthcare Innovation.